NFL Biosciences eyes Licensing Deals with Groundbreaking Smoking cessation Drug, NFL-101
Montpellier, France – November 11, 2025 – Pharmaceutical giants are keeping a close eye on NFL biosciences as the French biopharma company gears up to unveil crucial scientific data for NFL-101, its pioneering drug candidate designed to help smokers kick the habit. This isn’t just another nicotine patch; NFL-101 is carving out a unique niche in the addiction treatment landscape,and regulatory bodies are taking notice.
For sports enthusiasts who understand the dedication and discipline required to perform at the highest level, the concept of overcoming addiction resonates deeply. Think of the mental fortitude it takes to push through a grueling fourth quarter or the resilience needed after a tough loss. NFL Biosciences is aiming to harness that same spirit of overcoming challenges with NFL-101.
The company is poised to release key findings in the coming months that will solidify NFL-101’s distinctive scientific positioning. This is particularly critically important for pharmaceutical companies considering licensing the drug, as they’ll wont to understand exactly what makes NFL-101 a game-changer.
Upcoming Scientific Milestones: The Playbook for NFL-101’s Success
NFL Biosciences has laid out a clear roadmap, and two upcoming scientific milestones are generating significant buzz:
* Mechanism of Action (MOA) unveiled in January 2026: Get ready for some deep dives into the science behind NFL-101. Preliminary results from a proteomic analysis are expected to pinpoint neural and immune signaling markers that NFL-101 triggers. The goal? To compare these markers with those already known to be involved in tobacco dependence. This will be crucial in demonstrating how NFL-101’s original characteristics set it apart from every other smoking cessation product on the market. Imagine a quarterback having a fully new playbook that outsmarts the defense – that’s the kind of innovation NFL-101 is aiming for.
* In-Depth characterization in December 2025: Before the MOA reveal,NFL Biosciences will provide initial results from further analyses of NFL-101’s composition. This is all about ensuring the extracts are thoroughly understood and, critically, that the manufacturing process delivers consistent results batch after batch. Think of it like a star athlete’s training regimen – consistency and precision are key to peak performance.
These studies are part of a broader strategy announced on October 20, 2025, which underscores NFL Biosciences’ commitment to a comprehensive understanding of NFL-101’s composition and how it works.
NFL Biosciences: A New Player in Addiction Treatment
NFL Biosciences is a biopharmaceutical company based in the vibrant Montpellier region of France. Their mission is ambitious: to develop plant-based drug candidates that offer safer and more effective treatments for addiction.They’re not just looking to serve the U.S. market; their ambition is to bring these natural therapeutic solutions to the global population, including those in low- and middle-income countries.
Their flagship product, NFL-101, is a standardized tobacco leaf extract that’s already protected by three patent families. NFL Biosciences envisions NFL-101 as a natural, safe, and easy-to-administer alternative for smokers looking to quit. This approach could be a real game-changer, offering a personalized path to freedom from addiction.
Beyond NFL-101,the company is also developing NFL-301,a natural drug candidate aimed at reducing alcohol consumption. They also have a drug development project focused on treating cannabis use disorders.
NFL Biosciences shares are traded on Euronext Growth Paris under the ticker ALNFL. The company has also earned the designation of an “Innovative Company,” making it eligible for FCPI investment.
For sports fans, the pursuit of excellence and the overcoming of personal challenges are themes that resonate deeply. NFL Biosciences’ dedication to developing innovative, natural solutions for addiction treatment could represent a significant win for public health, much like a championship victory for a beloved team.
For more data, visit: www.nflbiosciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251111593795/en/
Contacts:
NewCap
Investor Relations | media Relations
Mathilde Bohin | Arthur Rouillé
Tel.: 01 44 71 94 94
Email: nfl@newcap.eu
NFL Biosciences
Bruno Lafont
Tel.: 04 11 93 76 67
Email: info@nflbiosciences.com
